164 related articles for article (PubMed ID: 24819188)
1. [Successful autologous haematopoietic stem cell transplantation in severe, therapy-resistant childhood Crohn's disease. Report on the first case in Hungary].
Kriván G; Szabó D; Kállay K; Benyó G; Kassa C; Sinkó J; Goda V; Arató A; Veres G
Orv Hetil; 2014 May; 155(20):789-92. PubMed ID: 24819188
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease.
Hommes DW; Duijvestein M; Zelinkova Z; Stokkers PC; Ley MH; Stoker J; Voermans C; van Oers MH; Kersten MJ
J Crohns Colitis; 2011 Dec; 5(6):543-9. PubMed ID: 22115372
[TBL] [Abstract][Full Text] [Related]
3. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the management of Crohn's disease.
Caprilli R; Angelucci E; Clemente V
Dig Liver Dis; 2008 Sep; 40(9):709-16. PubMed ID: 18430617
[TBL] [Abstract][Full Text] [Related]
5. [A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy].
Park SH; Jeen YT; Chun HR; Kim DI; Baeck CW; Kim YS; Chun HJ; Lee HS; Um SH; Choi JH; Kim CD; Ryu HS; Hyun JH
Korean J Gastroenterol; 2005 Oct; 46(4):297-301. PubMed ID: 16247274
[TBL] [Abstract][Full Text] [Related]
6. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
7. Complete clinical remission after high-dose immune suppression and autologous hematopoietic stem cell transplantation in severe Crohn's disease refractory to immunosuppressive and immunomodulator therapy.
Scimè R; Cavallaro AM; Tringali S; Santoro A; Rizzo A; Montalbano L; Casà A; Cottone M
Inflamm Bowel Dis; 2004 Nov; 10(6):892-4. PubMed ID: 15626911
[No Abstract] [Full Text] [Related]
8. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.
Cassinotti A; Annaloro C; Ardizzone S; Onida F; Della Volpe A; Clerici M; Usardi P; Greco S; Maconi G; Porro GB; Deliliers GL
Gut; 2008 Feb; 57(2):211-7. PubMed ID: 17895357
[TBL] [Abstract][Full Text] [Related]
9. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
[TBL] [Abstract][Full Text] [Related]
10. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
[TBL] [Abstract][Full Text] [Related]
11. [Acute appendicitis in a patient with perianal Crohn's disease receiving infliximab].
Szakács Z; Faluhelyi N; Fincsur A; Papp A; Vincze Á; Bajor J
Orv Hetil; 2018 Mar; 159(10):405-409. PubMed ID: 29504422
[TBL] [Abstract][Full Text] [Related]
12. Autologous haematopoietic stem cell transplantation in a patient with refractory Crohn's disease.
Kountouras J; Sakellari I; Tsarouchas G; Tsiaousi E; Michael S; Zavos C; Anastasiadou K; Stergiopoulos C; Anagnostopoulos A
J Crohns Colitis; 2011 Jun; 5(3):275-6. PubMed ID: 21575901
[No Abstract] [Full Text] [Related]
13. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
[TBL] [Abstract][Full Text] [Related]
14. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
[TBL] [Abstract][Full Text] [Related]
15. Basiliximab and infliximab for the treatment of steroid-refractory Crohn's disease.
Price M; Probert CS; Creed T
Am J Gastroenterol; 2008 Oct; 103(10):2665. PubMed ID: 18855871
[No Abstract] [Full Text] [Related]
16. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of infliximab treated pediatric patients with Crohn disease in Hungary].
Veres G; Szabó D; Várkonyi A; Tari B; Polgár M; B Kovács J; Horváth A; Tomsits E; Tokodi I; Bodánszky H; Dezsofi A; Szakos E; Vass N; Ruszinkó V; Kovács M; Müller KE; Arató A
Orv Hetil; 2010 Jan; 151(5):179-83. PubMed ID: 20083466
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of tumor necrosis factor-alpha inhibitors in fistulising perianal Crohn's disease].
Bor R; Farkas K; Bálint A; Szűcs M; Abrahám S; Baradnay G; Wittmann T; Szepes Z; Nagy F; Molnár T
Orv Hetil; 2013 Dec; 154(49):1943-8. PubMed ID: 24292112
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of Crohn's disease by infliximab. About 20 cases].
Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
[TBL] [Abstract][Full Text] [Related]
20. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
